Nanjing Bioheng Biotech Co , Ltd Announced UCAR T cell therapy product targeting CD7, code CTD401, received Orphan Drug Designation (ODD) from the U S Food and Drug Administration (FDA) for the treatment of T-cell acute lymphoblastic leukemia (T-ALL)
Simcere Pharmaceutical Group Limited (2096 HK) announced that the clinical trial application for trilaciclib, an innovative drug being developed in cooperation with G1 Therapeutics, INC (Nasdaq: GTHX), has been approved by NMPA
On June 4, 2021, Nanjing LeadsBiolab announced that the phase I clinical study on the treatment of advanced solid tumor with LBL-007 injection, an LAG-3 human antibody developed by Nanjing LeadsBiolab, had been completed
Nanjing KAEDI becomes the first Chinese Biotech enterprise on specific targeting NKG2DL CAR-T to get a patent authorization notice from USPTO